Radiation and chemo after surgery for salivary gland cancer
Part of Cancer, Ear, nose & throat clinical trials.
This study tests giving radiation and chemotherapy together after surgery for aggressive salivary gland cancers of the head and neck. It aims to see how well this standard treatment works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a salivary gland cancer in the head or neck area, and it is a high-grade type (fast-growing or aggressive).
- You had surgery to remove all visible cancer (with the goal of curing you), and the tumor was large, or had spread to lymph nodes, or the edges were not completely clear.
- You have not had radiation or chemotherapy for this type of cancer before.
- You are 18 or older, and you are generally healthy enough to be active and take care of yourself (WHO score 0 or 1).
- You do not have cancer that has spread to other parts of the body (no distant metastases).
- You have no serious uncontrolled medical conditions (like recent heart attack or severe infection) that would make chemo unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests giving nivolumab plus docetaxel and cisplatin before surgery and radiation for certain resectable, high-grade salivary gland cancers. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
This trial studies toripalimab (an immune medicine) combined with chemotherapy given before surgery for salivary gland cancer. It aims to shrink the tumor and improve outcomes by using treatment early, before the operation.
This study tests a combination of a targeted cancer drug (antibody-drug conjugate) and focused radiation therapy for salivary gland cancers that have come back or spread after initial treatment. It may help patients whose cancer didn't respond to standard options.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Hear when a new Locally Advanced Salivary Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.